Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0YTBHI
ADC Name	RBGO1-mcF
Synonyms	RBGO1-mcMMAF Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Endometrial cancer [ICD11:2C76] Investigative
Drug-to-Antibody Ratio	3.5
	3D MOL	2D MOL
Antibody Name	Anti-RAGE mAb RBGO1		Antibody Info
Antigen Name	Advanced glycosylation end product-specific receptor (AGER)		Antigen Info
Payload Name	Monomethyl auristatin F		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Maleimido-caproyl		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	McMMAF

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 60	%	HEC-1-A cells	Endometrial adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 60.00% (Day 20)	Positive RAGE expression (RAGE+++/++)
Method Description	Nude athymic mice were divided into three treatment groups of six mice each. Mice were treated with PBS (control) or RBGO1 ADC at either 3 mg/kg or 20mg/kg N intravenous injection. Bodyweight was measured at days 3, 6, 8, 13, 17 and 21 and mouse health assessed daily.
In Vivo Model	HEC-1-A CDX model
In Vitro Model	Endometrial adenocarcinoma	HEC-1-A cells		CVCL_0293

References

Ref 1	Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer. J Immunother Cancer. 2019 Oct 29;7(1):280. doi: 10.1186/s40425-019-0765-z.